Abbott Laboratories (NYSE: ABT) recently posted second quarter results that beat expectations, albeit slightly. Spinning off the company's pharmaceutical arm into AbbVie exposed a bloated, underperforming giant. Fortunately, the company is making strides to boost profitability and increase its presence in quickly growing markets.
The Street likes the results so far. Watch the slideshow to see if Abbott Labs can continue to impress in the quarters to come.